Approximately 40% of patients with Merkel cell carcinoma (MCC) develop recurrence or metastasis. Early detection can result in better outcomes, and effective surveillance is critical MCC management. We assessed whether circulating tumor DNA (ctDNA) accurately detect clinically evident and/or occult MCC. used the SignateraTM platform which tumor-specific mutations are identified from archival tu...